Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil-thiopental versus ketofol for anesthesia during electroconvulsive therapy in major depressive disorder
IRCT20210622051672N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Sep 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of remifentanil, thiopental, ketamine and propofol in major depressive disorder (MDD) (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoints: Mean arterial pressure, Heart rate and 5 more. Started Sep 2021; status: completed.
02
Drugs
remifentanilthiopentalketaminepropofol
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20210622051672N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210622051672N1.